Actas urologicas espanolas最新文献

{"title":"Consensus update on the therapeutic approach to patients with neurogenic detrusor overactivity.","authors":"A. Borau, J. Salinas, M. Allué, D. Castro-Diaz, M. Esteban, S. Arlandis, M. Vírseda, J. M. Adot","doi":"10.1016/j.acuroe.2024.05.013","DOIUrl":"https://doi.org/10.1016/j.acuroe.2024.05.013","url":null,"abstract":"","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"60 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141036584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The preoperative predictive factors for pathological T3a upstaging and positive surgical margin of clinical T1 renal cell carcinoma","authors":"G. Çil,&nbsp;M. Yilmaz,&nbsp;Y. Sahin,&nbsp;İ. Ulus,&nbsp;İ.O. Canıtez,&nbsp;İ.E. Kandıralı","doi":"10.1016/j.acuroe.2024.02.004","DOIUrl":"10.1016/j.acuroe.2024.02.004","url":null,"abstract":"<div><h3>Objectives</h3><p>The objective of this study is predict positive surgical margin (PSM) and pathological T3a (pT3a) upstaging in patients with clinical T1 (cT1) renal cell carcinoma (RCC).</p></div><div><h3>Materials and methods</h3><p>159 patients who underwent radical nephrectomy (RN) or partial nephrectomy (PN) for RCC. Patients’ demographic, laboratory, radiological and pathological data that could predict PSM and pT3a upstaging pre-operatively were evaluated. The categorical and continuous variables were compared between the patient groups with or without PSM and/or pT3a upstaging using Pearson’s chi-square test, and independent samples <em>t</em>-test or the Mann-Whitney U test, respectively.</p></div><div><h3>Results</h3><p>PT3a upstaging was detected in 32 (20.1%) patients, and PSM was detected in 28 (17.6%) patients. PT3a upstaging was detected in 27 and 5 patients who underwent open surgery and laparoscopic surgery, respectively (<em>P</em> &lt; .001). In addition, pT3a upstaging was detected in 6 and 26 patients who underwent RN and PN, respectively (<em>P</em> &lt; .001). Peritumoral fatty tissue thickness was 11.97 and 15.38 in the pT1 and pT3a patient groups, respectively (<em>P</em> = .022). In patients with pT3a upstaging, tumor size was larger, and renal nephrometry score and systemic immune-inflammation index (SII) were higher (<em>P</em> &lt; .001, <em>P</em> &lt; .001, and <em>P</em> = .022, respectively). It was determined that De Ritis ratio (DRR) and albumin-to-alkaline phosphatase (ALP) ratio (AAPR) parameters had significant prognostic values in predicting PSM (<em>P</em> = .024, and <em>P</em> = .001, respectively). ROC analysis indicated that tumor size predicted pT3a upstaging with 100% sensitivity and 98.6% specificity when its cut-off value was taken as 6.85 mm (AUC: 1.000, <em>P</em> &lt; .001). In addition, logistic regression analysis revealed AAPR and DRR as significant predictors of PSM (<em>P</em> &lt; .001, and <em>P</em> = .009, repsectively).</p></div><div><h3>Conclusion</h3><p>The findings of this study indicated that the surgical technique of choice and the type of operation, tumor size, RNS value, peritumoral fatty tissue thickness, HU values of peritumoral and tumor side fatty tissues, and DRR and SII values can predict pT3a upstaging of patients with cT1 RCC, and that AAPR and DRR values can predict PSM.</p></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"48 4","pages":"Pages 311-318"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139901058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determining PD-L1 expression in invasive urothelial carcinoma: Recommendations from the Spanish society of anatomic pathology.","authors":"F. Algaba","doi":"10.1016/j.acuroe.2024.05.015","DOIUrl":"https://doi.org/10.1016/j.acuroe.2024.05.015","url":null,"abstract":"","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"7 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141029345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Male infertility and sleep quality: Another key point to evaluate during the medical consultation","authors":"W.F. Fernández-Zapata,&nbsp;W.D. Cardona-Maya","doi":"10.1016/j.acuroe.2023.11.006","DOIUrl":"10.1016/j.acuroe.2023.11.006","url":null,"abstract":"","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"48 4","pages":"Page 335"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138178397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stereotactic body radiation therapy (SBRT): A new treatment option in renal cancer","authors":"F. Couñago ,&nbsp;F. López-Campos","doi":"10.1016/j.acuroe.2023.11.007","DOIUrl":"10.1016/j.acuroe.2023.11.007","url":null,"abstract":"","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"48 4","pages":"Pages 260-261"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138178398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementation of new treatments for BCG-unresponsive non-muscle-invasive bladder cancer. Considerations in Latin America","authors":"Mario I. Fernández","doi":"10.1016/j.acuroe.2024.03.003","DOIUrl":"10.1016/j.acuroe.2024.03.003","url":null,"abstract":"","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"48 4","pages":"Pages 257-259"},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140769965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of urinary tract cancer in the Spanish cohort of the IDENTIFY study","authors":"C. Toribio-Vázquez ,&nbsp;J. Gómez Rivas ,&nbsp;F. Amigo ,&nbsp;D.M. Carrión ,&nbsp;Á. Yebes ,&nbsp;M. Alonso-Bartolomé ,&nbsp;H. Ayllon ,&nbsp;A. Aguilera ,&nbsp;L. Martinez-Piñeiro ,&nbsp;M. Antón-Juanilla ,&nbsp;V. Crespo-Atín ,&nbsp;H. Otaola-Arca ,&nbsp;J.A. Herranz-Yague ,&nbsp;M.V. Munoz Rivero ,&nbsp;K.R. MacKenzie ,&nbsp;T.T. Shah ,&nbsp;C. Gao ,&nbsp;E. Zimmermann ,&nbsp;M. Jefferies ,&nbsp;A. Nambiar ,&nbsp;V. Kasivisvanathan","doi":"10.1016/j.acuroe.2023.08.001","DOIUrl":"10.1016/j.acuroe.2023.08.001","url":null,"abstract":"<div><h3>Introduction</h3><p>Malignant tumors of the urinary tract are associated with high morbidity and mortality, and their prevalence can vary worldwide. Recently, the IDENTIFY study has published results on the prevalence of urinary tract cancer at a global level. This study evaluates the prevalence of cancer within the Spanish cohort of the IDENTIFY study to determine whether the published results can be extrapolated to our population.</p></div><div><h3>Patients and methods</h3><p>An analysis of the data from the Spanish cohort of patients in the IDENTIFY study was performed. This is a prospective cohort of patients referred to secondary care with suspected cancer, predominantly due to hematuria. Patients were recruited between December 2017 and December 2018.</p></div><div><h3>Results</h3><p>A total of 706 patients from 9 Spanish centers were analyzed. Of these, 277 (39.2%) were diagnosed with cancer: 259 (36.7%) bladder cancer, 10 (1.4%) upper tract urothelial carcinoma, 9 (1.2%) renal cancer and 5 (0.7%) prostate cancer. Increasing age (OR 1.05 (95% CI 1.03−1.06; <em>P</em> &lt; 0.001)), visible hematuria (VH) OR 2.19 (95% CI 1.13–4.24; <em>P</em> = 0.02)) and smoking (ex-smokers: OR 2.11(95% CI 1.30–3.40; <em>P</em> = 0.002); smokers: OR 2.36 (95% CI 1.40–3.95; <em>P</em> = 0.001)) were associated with higher probability of bladder cancer.</p></div><div><h3>Conclusion</h3><p>This study highlights the risk of bladder cancer in patients with VH and smoking habits. Bladder cancer presented the highest prevalence; higher than the prevalence reported in previous series and presented in the IDENTIFY study. Future work should evaluate other associated factors that allow us to create cancer prediction models to improve the detection of cancer in our patients.</p></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"48 3","pages":"Pages 228-237"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10005464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of ureteric access sheath use during flexible ureteroscopy: A comparative study on efficacy and safety","authors":"M.M. Abdelfatah Zaza ,&nbsp;A. Farouk Salim ,&nbsp;T.A. El-Mageed Salem ,&nbsp;A. Mohammed Ezzat ,&nbsp;M. Hassan Ali","doi":"10.1016/j.acuroe.2023.10.005","DOIUrl":"10.1016/j.acuroe.2023.10.005","url":null,"abstract":"<div><h3>Objectives</h3><p>This study evaluates the impact of using an access sheath (AS) during flexible ureteroscopy<span> (fURS) for urolithiasis treatment, focusing on outcomes such as stone-free rate, operation time, and complications.</span></p></div><div><h3>Methods</h3><p>This prospective, randomized study was carried out at Badr Hospital, Helwan University, and Ain Shams University hospitals from August 2021 to August 2022. Patients were systematically randomized into two groups (fURS with AS: 33 patients and without AS: 31 patients) and underwent preoperative and postoperative assessments, including lab tests and imaging. Possible procedure-associated risks, such as failed stone access, pain, bleeding, and sepsis, were monitored.</p></div><div><h3>Results</h3><p>The two groups were found to be comparable in terms of demographic characteristics or preoperative stone findings (<em>p</em> &gt; 0.05 for all). However, operation duration was shorter in the No Sheath group (79.4 ± 15.3 min vs. 90.4 ± 16.7 min in the Sheath group, <em>p</em><span> = 0.008). Intraoperative complication rates, including failed access, operation termination, ureteric injury, and bleeding, were comparable in both groups (</span><em>p</em> &gt; 0.05). Postoperative stone-free rates (78.8% vs. 71.0%, <em>p</em> = 0.305) and mean residual stone size (2.7 ± 3.5 mm vs. 3.1 ± 3.1 mm, <em>p</em> = 0.687) showed no significant differences.</p></div><div><h3>Conclusions</h3><p>The present study suggests that fURS without an access sheath may offer an efficient and equally effective option for managing upper ureteric and renal stones. However, more studies with larger sample sizes and longer follow-up periods are required to validate these findings and to establish more precise indications for this approach.</p></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"48 3","pages":"Pages 204-209"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41224618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of the combination of prostate-specific antigen derivatives with multiparametric prostate magnetic resonance imaging scores on the negative predictive value of it in grey zone patients","authors":"C. Bostancı,&nbsp;D.Ö. Demir","doi":"10.1016/j.acuroe.2023.10.004","DOIUrl":"10.1016/j.acuroe.2023.10.004","url":null,"abstract":"<div><h3>Objective</h3><p>To calculate the negative predictive value (NPV) of negative multiparametric prostate magnetic resonance imaging (mpMRI), accepted as no lesions on images, when combined with prostate-specific antigen density (PSAD) and free/total prostate-specific antigen ratio (f/t PSA) in grey zone patients.</p></div><div><h3>Methods</h3><p>191 patients with PSA levels between 4−10 mg/mL and negative mpMRI were analyzed. The NPV of negative mpMRI was calculated according to a PSAD level of &lt;0.15 ng/mL/mL, f/t PSA ratio of &gt;0.15, and a combination of both. Patients were divided into three risk groups according to these two parameters, which were PSAD 0.01−0.07 ng/mL/mL and f/t PSA ratio ≥25 in a low-risk group, PSAD 0.08−0.15 ng/mL/mL, and f/t PSA ratio 0.15−0.24 in an intermediate-risk group and high-risk group, in which PSAD &gt; 0.15 ng/mL/mL and f/t PSA ratio &lt;15.</p></div><div><h3>Results</h3><p>NPV of negative mpMRI was 92.6% for clinically significant prostate carcinoma (CSPCa). It increased to 97.5% in a low-risk group and decreased to 33.3% for CSPCa in a high-risk group. NPV of negative mpMRI results were so close when combined with PSAD &lt; 0.15 ng/mL/mL and f/t PSA &gt; 15.</p></div><div><h3>Conclusion</h3><p>f/t PSA ratio might also be used to increase the NPV of mpMRI, like PSAD. We advise not to avoid prostate biopsy when PSAD is &gt;0.15 ng/mL/mL and the f/t PSA ratio is &lt;0.15. However, we need randomized controlled studies with more patients to confirm our study.</p></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"48 3","pages":"Pages 238-245"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41224620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of patients with localized prostate cancer and biochemical recurrence in Spain: A medical survey","authors":"R. Correa ,&nbsp;N. Vidal ,&nbsp;A. Quesada-García ,&nbsp;R. Marcos ,&nbsp;J. Muñoz del Toro ,&nbsp;J. Muñoz-Rodríguez","doi":"10.1016/j.acuroe.2023.08.002","DOIUrl":"10.1016/j.acuroe.2023.08.002","url":null,"abstract":"<div><h3>Introduction</h3><p>The management of patients with prostate cancer (PCa) is established in clinical practice guidelines, which are based on randomized studies according to the level of evidence. In Spain, the degree of compliance with these guidelines in clinical practice is unknown.</p></div><div><h3>Objectives</h3><p>To describe the profiles of PCa patients at the time of diagnosis and the management of patients with localized PCa and those with BCR in Spain.</p></div><div><h3>Materials &amp; methods</h3><p>A medical survey was conducted in specialized care (85 urologists [UROs], 64 radiation oncologists [ROs], and 21 medical oncologists [MOs]). Three questionnaires were developed for this study with 22 (UROs and ROs) or 21 questions (MOs).</p></div><div><h3>Results</h3><p>The annual incidence of PCa was 24,057 in participating hospitals (<em>N</em> = 131). The extrapolated annual incidence in Spain is 40,531 cases. The estimated prevalence of PCa in Spain is 221,689. Of note, 79% and 80% of patients seen by UROs and ROs, respectively had localized PCa at diagnosis. Biopsy was the most used diagnostic test among the three specialties, followed by abdominopelvic computer tomography. More than 90% of patients with BCR underwent standard tests. Next generation imaging tests and PET-choline/PSMA are still used residually. Most patients with localized PCa are currently treated with either surgery or radiotherapy, while for BCR patients, UROs and ROs prefer radiotherapy and MOs androgen deprivation therapy alone or in combination.</p></div><div><h3>Conclusion</h3><p>This study describes patient profiles at the time of diagnosis and provides an overview of the current therapeutic management of localized PCa and BCR in clinical practice in Spain.</p></div>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":"48 3","pages":"Pages 218-227"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2173578623001002/pdfft?md5=98e0c64d8ebb8a4637c34d8285caad92&pid=1-s2.0-S2173578623001002-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10380038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}